Sun Pharma Q3 profit slides 75% to Rs365 crore on weak US sales
Sun Pharma reports a net profit of Rs365 crore in the December 2017 quarter compared to a net profit of Rs1,472 crore a year earlier
Bengaluru: India’s largest drugmaker Sun Pharmaceutical Industries Ltd reported a 75% plunge in third-quarter net profit on Wednesday as pricing pressures in the United States, its biggest market, hit sales.
Sun Pharma, along with other Indian pharmaceutical companies, has been battling increased competition in the generics market and greater pricing scrutiny in the United States.
The drugmaker has also struggled as some of its products were banned from sale in the United States because the factories that made them did not meet US quality standards. It was also hit by adjustments for US tax reforms in the third quarter.
Its net profit of Rs365 crore ($57 million) for the October-December quarter was its smallest profit in over two and a half years, and well below analysts forecasts of Rs912 crore in a Reuters poll.
The company said its US sales slumped 35% to $328 million in the quarter, hurt by lower sales of generic versions of cancer drug imatinib and olmesartan, which is used in the treatment of high blood pressure.
US sales accounted for nearly a third of the company’s total sales, which fell 14% to Rs659 crore.
The company said its profit was also hit by a one-off deferred tax adjustment of Rs513 crore on account of tax reforms in the United States.
Sun Pharma shares closed 2.53% lower at Rs574.45 on BSE, while the Sensex was down 0.42% at 34,155.95 points. Reuters
- Q2 results: HDFC Bank net profit rises 20.6% to Rs 5006 crore
- Govt, board eye asset sales to turn IL&FS around in six months
- Jet Airways sets jet sale, leaseback plan in motion to raise $800 mn
- Lenders accept ArcelorMittal resolution plan for Essar Steel
- #MeToo: Publicis India sacks executive creative director Ishrath Nawaz
Editor's Picks »
- India to put former top climate change official Rajendra Pachauri on trial for sexual harassment
- Rahul Gandhi hits out at KCR, claims Telangana reeling under debt
- Deve Gowda-Siddaramaiah display rare bonhomie ahead of Karnataka by-polls
- Govt allocates Rs 144 crore to AYUSH ministry for alternative medicines
- Esperanto, A language whose time never came
- Policy rethink and higher volumes to aid container shippers
- DCB Bank delivers a strong Q2 but pressure on margins foreseen
- Havells India: Rising costs give a jolt to profitability in September quarter
- All’s well at Mindtree, except for high client concentration risk
- India’s rising steel demand is making companies starry-eyed